The downregulation of LRRK2 protein after birabresib single treatment can be explained by an observed lower BRD4 DNA binding, after JQ1, reported in publicly available chromatin immunoprecipitation (ChIP)‐sequencing dataset obtained from a GCB DLBCL cell line (SRP022129) (Figure S7). The gene discussed is LRRK2; the disease is diffuse large B-cell lymphoma.